AEON Biopharma, Inc. (AEON)

1.7300 +0.0700 (+4.22%) At close: 04:00PM EDT

AEON Biopharma, Inc.

5 Park Plaza
Suite 1750
Irvine, CA 92614
United States
(949) 354-6499
https://www.aeonbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 10

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Marc Forth	President, CEO & Director	948.75k	N/A	1971
Mr. Alex Wilson	Executive VP, Chief Legal Officer & Corporate Secretary	517.4k	N/A	1987
Dr. Chad K. Oh M.D.	Chief Medical Officer	561k	N/A	1959
Mr. Peter A. Reynolds CPA	Interim Chief Financial Officer	N/A	N/A	1958

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Corporate Governance

AEON Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.